A carregar...
In Vitro Safety “Clinical Trial” of the Cardiac Liability of Hydroxychloroquine and Azithromycin as COVID19 Polytherapy
Despite global efforts, there are no effective FDA-approved medicines for the treatment of SARS-CoV-2 infection. Potential therapeutics focus on repurposed drugs, some with cardiac liabilities. Here we report on a preclinical drug screening platform, a cardiac microphysiological system (MPS), to ass...
Na minha lista:
| Publicado no: | bioRxiv |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cold Spring Harbor Laboratory
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7781317/ https://ncbi.nlm.nih.gov/pubmed/33398282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.12.21.423869 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|